A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine

Journal of Clinical Psychopharmacology

Volumn 32, Issue 1, 2012, Pages 120-126

  Nardi, Antonio E ^a   Freire, Rafael C ^a   Mochcovitch, Marina D ^a   Amrein, Roman ^a   Levitan, Michelle N ^a   King, Anna L ^a   Valença, Alexandre M ^a,b   Veras, André B ^a   Paes, Flávia ^a   Sardinha, Aline ^a   Nascimento, Isabella ^a   De Melo Neto, Valfrido L ^a,c   Dias, Gisele P ^a   E Silva, Adriana Cardoso De O ^a,b   Soares Filho, Gastão L ^a,d   Da Costa, Rafael T ^a   Mezzasalma, Marco A ^a   De Carvalho, Marcele R ^a   De Cerqueira, Ana C ^a   Hallak, Jaime E ^e   Crippa, José A ^e   Versiani, Marcio ^a   more..

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^c Alagoas Federal University   (Brazil)

^d Pro Cardíaco Hospital   (Brazil)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

clonazepam; panic attacks; panic disorder; paroxetine

Indexed keywords

CLONAZEPAM; PAROXETINE;

ADULT; AGITATION; AGORAPHOBIA; ANXIETY; APPETITE; ARTICLE; BEDTIME DOSAGE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PROTOCOL; CONCENTRATION LOSS; CONSTIPATION; CONTROLLED STUDY; DEPERSONALIZATION; DIARRHEA; DISEASE SEVERITY; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERHIDROSIS; INSOMNIA; LONG TERM CARE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MONOTHERAPY; NATURALISTIC INQUIRY; NAUSEA; NIGHTMARE; PANIC; PARALLEL DESIGN; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; VOMITING; WEAKNESS; WEIGHT CHANGE; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ADULT; ANTICONVULSANTS; BRAZIL; CLONAZEPAM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTERVIEW, PSYCHOLOGICAL; LONG-TERM CARE; MALE; MIDDLE AGED; PANIC DISORDER; PAROXETINE; PERSONALITY INVENTORY; PROSPECTIVE STUDIES; RETREATMENT; SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 84855340749     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31823fe4bd     Document Type: Article

References (31)

1. Goodwin RD, Faravelli C, Rosi S, et al. The epidemiology of panic disorder and agoraphobia in Europe. Eur Neuropsychopharmacol. 2005;15:435-443. (Pubitemid 40943547)
2. Kessler RC, Chiu WT, Jin R, et al. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2006;63:415-424.
3. Roy-Byrne PP, Wagner AW, Schraufnagel TJ. Understanding and treating panic disorder in the primary care setting. J Clin Psychiatry. 2005;66(suppl 4):16-22. (Pubitemid 40637721)
4. Rosenbaum JF, Pollack MH, Pollock RA. Clinical issues in the long-term treatment of panic disorder. J Clin Psychiatry. 1996;57(suppl 10):44-48.
5. Katschnig H, Amering M. The long-term course of panic disorder and its predictors. J Clin Psychopharmacol. 1998;18(suppl 2):6-11.
6. Davidson JR. The long-term treatment of panic disorder. J Clin Psychiatry. 1998;59(suppl 8):17-21.
7. Andersch S, Hetta J. A 15-year follow-up study of patients with panic disorder. Eur Psychiatry. 2003;18:401-408. (Pubitemid 38009823)
8. American Psychiatric Association, 2009. Practice guideline for the treatment of patients with panic disorder. Available at: http://www. psychiatryonline.com/pracGuide/loadGuidelinePdf.aspx?file=PanicDisorder-2e- PracticeGuideline. Accessed July 23, 2010.
9. Lecrubier Y, Judge R. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand. 1997;95:153-160. (Pubitemid 27092887)
10. Dannon PN, Lowengrub K, Iancu I, et al. Paroxetine in panic disorder: clinical management and long-term follow-up. Expert Rev Neurother. 2004;4:191-198. (Pubitemid 38315939)
11. Bruce SE, Vasile RG, Goisman RM, et al. Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia? Am J Psychiatry. 2003;160:1432-1438. (Pubitemid 41070918)
12. Susman J, Klee B. The role of high-potency benzodiazepines in the treatment of panic disorder. Prim Care Companion J Clin Psychiatry. 2005;7:5-11. (Pubitemid 41711464)
13. Nardi AE, Valenca AM, Freire RC, et al. Randomized, open naturalistic acute treatment of panic disorder with clonazepam or paroxetine. J Clin Psychopharmacol. 2011;31:259-261.
14. Valena AM, Nardi AE, Nascimento I, et al. Double-blind clonazepam vs placebo in panic disorder treatment. Arq Neuropsiquiatr. 2000;58:1025-1029.
15. Moroz G, Rosenbaum JF. Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a placebo-controlled, multicenter study using optimized dosages. J Clin Psychiatry. 1999;60:604-612. (Pubitemid 29451557)
16. Nardi AE, Valena AM, Nascimento I, et al. A three-year follow-up study of patients with the respiratory subtype of panic disorder after treatment with clonazepam. Psychiatry Res. 2005;137:61-70. (Pubitemid 41550129)
17. Chouinard G. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry. 2004;65(suppl 5):7-12.
18. Pollack MH, Doyle AC. Treatment of panic disorder: focus on paroxetine. Psychopharmacol Bull. 2003;37(suppl 1):53-63.
19. Mitte K. A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. J Affect Disord. 2005;88:27-45. (Pubitemid 41160411)
20. Rickels K, Schweizer E. Panic disorder: long-term pharmacotherapy and discontinuation. J Clin Psychopharmacol. 1998;18(6 suppl 2): 12SY18S.
21. Baldwin DS, Cooper JA, Huusom AK, et al. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. Int Clin Psychopharmacol. 2006;21:159-169. (Pubitemid 43740307)
22. Nardi AE, Freire RC, Valena AM, et al. Tapering clonazepam in patients with panic disorder after at least 3 years of treatment. J Clin Psychopharmacol. 2010;30:290-293.
23. Dannon PN, Iancu J, Cohen A, et al. Three year naturalistic outcome study of panic disorder patients treated with paroxetine. BMC Psychiatry. 2004;4:16.
24. Marchesi C. Pharmacological management of panic disorder. Neuropsychiatr Dis Treat. 2008;4:93-106. (Pubitemid 351460983)
25. Woods JH, Katz JL, Winger G. Benzodiazepines: use, abuse, and consequences. Pharmacol Rev. 1992;44:151-347.
26. Golombok S, Moodley P, Lade M. Cognitive impairment in long-term benzodiazepine users. Psychol Med. 1998;18:365-374.
27. Lucki I, Rickels K. The effect of anxiolytic drugs on memory in anxious subjects. Psychopharmacol Ser. 1988;6:128-139.
28. Kennedy SH, Eisfeld BS, Dickens SE, et al. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry. 2000;61:276-281. (Pubitemid 30305369)
29. Gunasekara NS, Noble S, Benfield P. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. Drugs. 1998;55:85-120. (Pubitemid 28035127)
30. Hriscu A, Gherase F, Nǎstasǎ V, et al. An experimental study of tolerance to benzodiazepines [in Romanian]. Rev Med Chir Soc Med Nat Iasi. 2002;106:806-811.
31. Bateson AN. Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal. Curr Pharm Des. 2002;8:5-21. (Pubitemid 34449900)